BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Smita Kothari

​​

Session 12 – Recent Development of Game-Changing Tumor Agnostic Therapeutics

Date:23 July (Friday)
Time:  12:20 – 13:50 (GMT+8)

Smita Kothari

Executive Director in the Center for Observational and Real world Evidence
Merck Sharp & Dohme (I.A.) LLC, Taiwan Branch

Dr. Smita Kothari is an Executive Director in the Center for Observational and Real world Evidence at Merck & Co Inc. where she leads a team responsible for generating pan tumor real world evidence (RWE) strategies. In this role, Dr. Kothari leads the group focused on building data and analytic capabilities that enable oncology RWE generation.  Dr. Kothari joined Merck in 2011 and has held positions of increasing responsibility leading HTA reimbursement strategies for products across both, the Vaccines and Oncology franchises, respectively. During her tenure at Merck, she has made significant contributions in design and implementation of outcomes research & health economic studies for early development, launch, and in-line oncology products and vaccines. In oncology, she has led research reflective of payer needs in both tumor specific and tumor agnostic indications.  She has vast experience engaging with various health authorities across the globe to seek scientific advice and strengthen the value proposition for several products. Prior to joining Merck, she was a part of the Health Economics team at Astellas Pharma US Inc. Dr. Kothari is widely published and has served as a reviewer for many leading journals.  She received a PhD in Pharmacy Administration and an MBA with Health Economics concentration from the University of Louisiana and graduated with a Bachelor's degree in Pharmacy from the University of Mumbai, India.

 

Speech title & Synopsis

Bridge Between Clinical Trials and the Real World: Foundations for Real-world Evidence in Asia Pacific

.